# OnCo record tisagenlecleucel (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/tisagenlecleucel/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "tisagenlecleucel" ;
  schema:name "Tisagenlecleucel"@en ;
  schema:description "Tisagenlecleucel was the first CAR-T therapy ever approved (2017), for children and young adults whose leukaemia had come back after everything else."@en ;
  schema:url <https://onco.cc/drugs/tisagenlecleucel/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Tisagenlecleucel> ;
  owl:sameAs <http://www.wikidata.org/entity/Q30314624> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Tisagenlecleucel> ;
  onco:status "approved" ;
  onco:modality "CAR-T (CD19)" ;
  schema:alternateName "Kymriah" ;
  onco:approval "US 2017: Relapsed/refractory B-ALL, patients up to 25 years", "US 2018: Relapsed/refractory DLBCL", "US 2022: Relapsed/refractory follicular lymphoma" ;
  onco:acceleratedApproval "US 2022-05-27: Treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy" ;
  onco:cancers <https://onco.cc/cancers/all-leukemia/>, <https://onco.cc/cancers/all-paediatric-relapsed/>, <https://onco.cc/cancers/dlbcl/> ;
  onco:technologies <https://onco.cc/technologies/car-t/> ;
  onco:targets <https://onco.cc/targets/cd19/> ;
  onco:companies <https://onco.cc/companies/novartis/> ;
  onco:terms <https://onco.cc/terms/crs/>, <https://onco.cc/terms/icans/> ;
  onco:trials <https://onco.cc/trials/eliana/>, <https://onco.cc/trials/nct04094311/>, <https://onco.cc/trials/nct05888493/>, <https://onco.cc/trials/nct03876769/> .